Conditions/Peritoneal Metastasis, CRS & HIPEC/Chapter
CRS / HIPEC Eligibility
Performance status, histology, PCI, and a realistic chance of complete cytoreduction gate the conversation.
Eligibility starts with tumor biology (e.g., selected colorectal, appendiceal mucinous/PMP spectrum, some ovarian, some mesothelioma pathways) and a probability of clearing disease (CC-0/1). Good performance status and controllable systemic disease matter. Gastric peritoneal metastases remain highly selective and controversial. Declining CRS/HIPEC when futile is protective, not hopelessness. Complete cytoreduction odds and histology-specific evidence should be stated before any HIPEC promise.
Figure labels (English)
- CRS
- HIPEC
- Peritoneum
Who may be a candidate?
- Selected peritoneal metastases with low-to-moderate PCI and CC-0/1 likely
- Adequate fitness for prolonged major surgery
- Histologies where center protocols support CRS ± HIPEC discussion
Possible advantages
- Complete CRS can meaningfully alter natural history in the right biology
- Combines resection of involved organs only as needed for clearance
- HIPEC retained as a selective tool, not a mandatory stamp
Limits & realistic expectations
- High PCI / unresectable zones exclude many patients
- Major morbidity and long recovery
- Colorectal oxaliplatin HIPEC lacks OS benefit in PRODIGE-7
Step-by-step overview
- 1
Define the clinical question
Confirm why crs / hipec eligibility is being discussed now — diagnosis, staging, treatment, or surveillance.
- 2
Gather records
Collect imaging, endoscopy, pathology, and prior operative notes before decisions lock.
- 3
Risk-stratify
Match urgency to red flags, labs, and imaging rather than labels alone.
- 4
Choose a pathway
Compare observation, medical therapy, endoscopy, and surgery with expected recovery.
- 5
Plan follow-up
Agree on review timing, warning symptoms, and who to call after hours.
Key points
- How crs / hipec eligibility fits the pathwayTap for details
In CRS/HIPEC, “CRS / HIPEC Eligibility” is a decision node inside a longer journey: symptoms, confirmation, risk stratification, treatment choice, and follow-up. Reading this chapter alongside the hub overview helps you ask better questions in clinic.
- What clinicians weighTap for details
CRS aims for complete cytoreduction; HIPEC may be added in selected cases. Completeness of cytoreduction usually drives candidacy. Your age, comorbidities, prior operations, imaging quality, pathology details, and personal goals can reasonably change the sequence even when the label is the same.
- Disease extent and urgency
- Fitness for anesthesia or procedure
- Alternatives and expected recovery
- Follow-up intensity you can complete
- Warning signs worth urgent reviewTap for details · key note inside
Severe progressive pain, fever with rigidity, vomiting with obstipation, heavy bleeding, sudden breathlessness, or a rapidly worsening wound/stoma problem should not wait for a routine slot. When in doubt, seek urgent assessment and bring prior reports.
- Severe progressive pain
- Fever with peritoneal signs
- Vomiting with inability to pass stool/gas
- Heavy bleeding or collapse
- Practical preparation for your visitTap for details
Bring endoscopy or operative reports, pathology, imaging discs, medication lists, and a short written list of priorities. Ask how this step changes if molecular results, MRI, or second-look findings differ from the preliminary plan.
- Shared decisions and realistic expectationsTap for details
Educational pages cannot replace examination. Two patients with the same crs / hipec eligibility label may leave with different plans after staging. Ask what success looks like at three months and one year, and what the rescue plan is if the first pathway fails.
- Selection criteria matterTap for details · key note inside
Pathways such as crs / hipec eligibility work only with clear entry criteria, defined follow-up, and an agreed plan if the pathway fails. In the context of CRS/HIPEC, discuss how this point changes timing, alternatives, and follow-up with your surgical team before locking a plan.
- CRS first, HIPEC secondTap for details · key note inside
Completeness of cytoreduction is usually the dominant prognostic factor discussed; HIPEC is not automatically added to every CRS. In the context of CRS/HIPEC, discuss how this point changes timing, alternatives, and follow-up with your surgical team before locking a plan.
- ImportantTap for details · key note inside
Educational information only — not a substitute for clinical evaluation or personalized advice.
Frequently asked questions
- Who is typically discussed for CRS/HIPEC?Tap for details
Selected patients with peritoneal disease where complete cytoreduction appears achievable and fitness allows major surgery.
- What makes someone ineligible?Tap for details
Widespread unresectable disease, poor performance status, or biology where major CRS is unlikely to help.
- Is colorectal peritoneal disease always offered HIPEC?Tap for details
No. Evidence boundaries (including oxaliplatin HIPEC debates) should be explained openly.
- What imaging is needed?Tap for details
High-quality cross-sectional staging and surgical assessment of resectability.
More chapters in this hub
Appointment / info
Educational information only; not a substitute for clinical evaluation.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.